[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

AU2001266033A1 - Formulation based on heparin, glycosaminoglycan or heparinoid, use of the formulation and the formulation base - Google Patents

Formulation based on heparin, glycosaminoglycan or heparinoid, use of the formulation and the formulation base

Info

Publication number
AU2001266033A1
AU2001266033A1 AU2001266033A AU6603301A AU2001266033A1 AU 2001266033 A1 AU2001266033 A1 AU 2001266033A1 AU 2001266033 A AU2001266033 A AU 2001266033A AU 6603301 A AU6603301 A AU 6603301A AU 2001266033 A1 AU2001266033 A1 AU 2001266033A1
Authority
AU
Australia
Prior art keywords
formulation
heparinoid
glycosaminoglycan
heparin
formulations
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001266033A
Inventor
Jorg Breitenbach
Robert Heger
Dieter Herr
Volker Laux
Jorg Rosenberg
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
BASF SE
Original Assignee
BASF SE
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by BASF SE filed Critical BASF SE
Publication of AU2001266033A1 publication Critical patent/AU2001266033A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/727—Heparin; Heparan
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Biophysics (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Transplantation (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Oncology (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Materials For Medical Uses (AREA)

Abstract

The present invention relates to formulations based on at least one heparin, glycosaminoglycan or heparinoid and on a formulation base with a lipid component and a polymer component. The use of this formulation as drug form for oral administration of at least one heparin, glycosaminoglycan or heparinoid, and also a process for producing the formulations by mixing the formulation components to form a plastic mixture and, where appropriate, to manufacture the formulations as drug form, advantageously using melt extrusion, are described. The lipid component advantageously has active ingredient-promoting properties, while the polymer component is soluble or swellable. At least parts of the lipid component are embedded in a polymer matrix, preferably in the form of a molecular dispersion. The formulations can form emulsions in water or aqueous liquids.
AU2001266033A 2000-05-30 2001-05-29 Formulation based on heparin, glycosaminoglycan or heparinoid, use of the formulation and the formulation base Abandoned AU2001266033A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE10026699A DE10026699A1 (en) 2000-05-30 2000-05-30 Formulation based on heparin, glycosaminoglycan or heparinoid and use of the formulation and the formulation base
DE10026699 2000-05-30
PCT/EP2001/006115 WO2001091729A1 (en) 2000-05-30 2001-05-29 Formulation based on heparin, glycosaminoglycan or heparinoid, use of the formulation and the formulation base

Publications (1)

Publication Number Publication Date
AU2001266033A1 true AU2001266033A1 (en) 2001-12-11

Family

ID=7644040

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001266033A Abandoned AU2001266033A1 (en) 2000-05-30 2001-05-29 Formulation based on heparin, glycosaminoglycan or heparinoid, use of the formulation and the formulation base

Country Status (13)

Country Link
US (1) US7393840B2 (en)
EP (1) EP1284717B1 (en)
JP (1) JP5198708B2 (en)
CN (1) CN100391440C (en)
AT (1) ATE349202T1 (en)
AU (1) AU2001266033A1 (en)
BR (1) BR0111257A (en)
CA (1) CA2409828C (en)
DE (2) DE10026699A1 (en)
ES (1) ES2278750T3 (en)
NO (2) NO20025759L (en)
RU (1) RU2278658C2 (en)
WO (1) WO2001091729A1 (en)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7364752B1 (en) 1999-11-12 2008-04-29 Abbott Laboratories Solid dispersion pharamaceutical formulations
EP1175205B1 (en) * 1999-11-12 2006-06-14 Abbott Laboratories Solid dispersion comprising ritonavir, fenofibrate or griseofulvin
DE10026698A1 (en) * 2000-05-30 2001-12-06 Basf Ag Self-emulsifying active ingredient formulation and use of this formulation
PT1345612E (en) * 2000-12-16 2005-06-30 Aventis Pharma Gmbh USE OF REDUCED MOLECULAR MASS HEPARIN FOR THE TREATMENT OF OSTEOARTHROSIS
GB0205868D0 (en) * 2002-03-13 2002-04-24 Univ Nottingham Polymer composite with internally distributed deposition matter
AU2003303301B2 (en) 2002-05-03 2008-08-07 Massachusetts Institute Of Technology Delta4,5 glycuronidase and uses thereof
SE0201922D0 (en) 2002-06-20 2002-06-20 Ltp Lipid Technologies Provide Anticoagulant Composition
US8025899B2 (en) 2003-08-28 2011-09-27 Abbott Laboratories Solid pharmaceutical dosage form
US8377952B2 (en) * 2003-08-28 2013-02-19 Abbott Laboratories Solid pharmaceutical dosage formulation
EP1675890A1 (en) * 2003-10-23 2006-07-05 The University Of Nottingham Preparing active polymer extrudates
US7988962B2 (en) * 2003-12-02 2011-08-02 Universiteit Gent Use of polysulphated alginate in cellular matrices
EP1537871A1 (en) * 2003-12-04 2005-06-08 Aventis Pharma S.A. Enoxaparin for the treatment of cancer
US7563780B1 (en) * 2004-06-18 2009-07-21 Advanced Cardiovascular Systems, Inc. Heparin prodrugs and drug delivery stents formed therefrom
JP5258144B2 (en) * 2004-12-21 2013-08-07 株式会社分子生理化学研究所 Method for producing solid coenzyme Q10 oral preparation with improved absorbability
US7691830B2 (en) * 2005-02-17 2010-04-06 Clive Elson Method and composition for treatment of a mucosal tissue disorder
MY148074A (en) * 2005-05-10 2013-02-28 Novartis Ag Pharmaceutical compositions comprising imatinib and a release retardant
US8802156B2 (en) * 2007-11-14 2014-08-12 Laboratorios Farmacéuticos Rovi, S.A. Pharmaceutical forms for the release of active compounds
GB0812742D0 (en) * 2008-07-11 2008-08-20 Critical Pharmaceuticals Ltd Process
WO2010068891A2 (en) * 2008-12-11 2010-06-17 L'oreal S.A. Lengthening mascara composition
WO2010113176A2 (en) * 2009-03-31 2010-10-07 Reliance Life Sciences Pvt. Ltd. Novel copolymers for controlled release delivery system
ES2363964B1 (en) 2009-11-20 2012-08-22 Gp Pharm, S.A. CAPSULES OF PHARMACEUTICAL ACTIVE PRINCIPLES AND ESTERS OF POLYINSATURATED FATTY ACIDS.
WO2011088418A2 (en) * 2010-01-15 2011-07-21 Mount Sinai School Of Medicine Inhibition of tnf-alpha induced activation of nfkb by pentosan polysulfate
US10897918B1 (en) * 2013-03-15 2021-01-26 Mccormick & Company, Incorporated Extrusion encapsulation with narrow particle size and shape distribution, high solubility, and low surface oil
WO2014142938A1 (en) * 2013-03-15 2014-09-18 Aihol Corporation Pharmaceutical formulation containing glycosaminoglycan
US9539265B2 (en) 2013-03-15 2017-01-10 Aihol Corporation Pharmaceutical formulation containing glycosaminoglycan
JP6877996B2 (en) * 2016-12-27 2021-05-26 小林製薬株式会社 Topical composition
JP6877997B2 (en) * 2016-12-27 2021-05-26 小林製薬株式会社 Topical composition
US11642366B2 (en) 2018-06-03 2023-05-09 Glycomira Therapeutics, Inc. Methods for preventing a serious health consequence and/or tissue damage after exposure to ionizing radiation and/or chemotherapy
US20210069237A1 (en) * 2019-09-09 2021-03-11 Harrow Ip, Llc Pharmaceutical compositions comprising heparinoids and methods for preparing thereof

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1107041A (en) * 1913-10-25 1914-08-11 Benjamin H Cook Coupling device.
JPS58101311A (en) * 1981-12-11 1983-06-16 Toshiba Corp Polyphase voltage and current converting circuit
DE3331009A1 (en) * 1983-08-27 1985-03-14 Basf Ag, 6700 Ludwigshafen METHOD FOR INCREASING THE ENTERAL RESORBABILITY OF HEPARIN OR. HEPARINOIDS AND THE SO AVAILABLE HEPARIN OR HEPARINOID PREPARATION
JPS6054313A (en) * 1983-09-01 1985-03-28 Terumo Corp Heparin composition absorbable through intestine
EP0318512B1 (en) * 1986-08-18 1998-06-17 Emisphere Technologies, Inc. Delivery systems for pharmacological agents
SE9200951D0 (en) * 1992-03-27 1992-03-27 Kabi Pharmacia Ab PHARMACEUTICAL COMPOSITION CONTAINING A DEFINED LIPID SYSTEM
US5346701A (en) * 1993-02-22 1994-09-13 Theratech, Inc. Transmucosal delivery of macromolecular drugs
SE9302135D0 (en) * 1993-06-18 1993-06-18 Kabi Pharmacia Ab NEW PHARMACEUTICAL COMPOSITION
DE69434626D1 (en) * 1993-11-17 2006-04-20 Athena Neurosciences Inc TRANSPARENT LIQUID FOR THE ADMINISTRATION OF CAPTIVATED MEDICAMENTS
DE19531277A1 (en) * 1995-08-25 1997-02-27 Basf Ag Use of lipids as an aid in the production of solid dosage forms by the melt extrusion process
FR2775188B1 (en) 1998-02-23 2001-03-09 Lipha IMMEDIATE RELEASE ORAL EXTENDED RELEASE GALENIC FORM COMPRISING AN ABSORPTION PROMOTING AGENT AND USE OF THE ABSORPTION PROMOTING AGENT
JP2002505307A (en) 1998-03-05 2002-02-19 ファレス ファーマシューティカル リサーチ エヌブイ Pharmaceutical compositions and uses thereof
US6267985B1 (en) 1999-06-30 2001-07-31 Lipocine Inc. Clear oil-containing pharmaceutical compositions
US6309663B1 (en) * 1999-08-17 2001-10-30 Lipocine Inc. Triglyceride-free compositions and methods for enhanced absorption of hydrophilic therapeutic agents

Also Published As

Publication number Publication date
NO20025759L (en) 2003-01-14
DE10026699A1 (en) 2001-12-06
RU2278658C2 (en) 2006-06-27
WO2001091729A1 (en) 2001-12-06
CA2409828A1 (en) 2001-12-06
ATE349202T1 (en) 2007-01-15
NO20025755D0 (en) 2002-11-29
ES2278750T3 (en) 2007-08-16
CN1450891A (en) 2003-10-22
EP1284717A1 (en) 2003-02-26
DE50111738D1 (en) 2007-02-08
EP1284717B1 (en) 2006-12-27
BR0111257A (en) 2003-06-10
NO20025759D0 (en) 2002-11-29
CN100391440C (en) 2008-06-04
JP2003534370A (en) 2003-11-18
CA2409828C (en) 2010-08-03
JP5198708B2 (en) 2013-05-15
US20030161884A1 (en) 2003-08-28
US7393840B2 (en) 2008-07-01

Similar Documents

Publication Publication Date Title
AU2001266033A1 (en) Formulation based on heparin, glycosaminoglycan or heparinoid, use of the formulation and the formulation base
BRPI0410956A (en) polyethylene oxide based films and drug delivery systems made from them
PT1061900E (en) COMPOSITIONS AND METHODS FOR LIBERATION OF A DRUG
AU2001279631A1 (en) Self-emulsifying active substance formulation and use of this formulation
WO2004060405A8 (en) Tissue reactive compounds and compositions and uses thereof
BRPI0416032A (en) excipients in drug delivery vehicles
WO2004112713A3 (en) Drug polymer complexes
ATE427760T1 (en) ERODABLE POLYMERS FOR INJECTION
AU2003281343A1 (en) Polymeric compositions containing polymers and ionic liquids
BR0106238B1 (en) molding dough having good blow molding capacity, as well as use of said molding dough and molded article containing it.
BR0212475A (en) Pharmaceutical Compositions
DE60135486D1 (en) COMPOSITIONS FOR DELAYED DELIVERY OF HYDROPHOBIC MEDICAMENTS AND METHOD FOR THE PRODUCTION THEREOF
WO2002000171A3 (en) Composition for delivery of hematopoietic growth factor
MXPA03011784A (en) Pharmaceutical compositions of dispersions of drugs and neutral polymers.
GEP20063917B (en) Pulmonary administration of chemically modified insulin
ATE536869T1 (en) GLUCAN FILM BASED DRUG DELIVERY SYSTEMS
BR0307893A (en) Ophthalmic formulation with gum system
BR0113663A (en) Pectin Film Compositions
MXPA05003591A (en) Cyclodextrin-based materials, compositions and uses related thereto.
DE69803940D1 (en) OPHTHALMIC COMPOSITION WITH EXTENDED RELEASE CONTAINING WATER-SOLUBLE MEDICINAL PRODUCTS
BRPI0411678A (en) nanoparticles of hyaluronic acid
DE60326859D1 (en) DRUGS ADMINISTRATION
ATE362776T1 (en) SWELLABLE HYDROGEL-FORMING POLYMERS WITH LOW FINE DUST CONTENT
ES2168855T3 (en) PHARMACEUTICAL COMPOSITIONS IN THE FORM OF POLYMER MICROPARTICLES OBTAINED BY EXTRUSION AND SPHEROIDIZATION.
BRPI0411954A (en) nanoparticles of polyoxyethylene derivatives and their method of preparation